Spruce Biosciences to Participate in the Craig-Hallum Biotech Catalyst Conference
Business Wire•15/10/2026•16:05 ET
0
Key Highlights
- ➤Spruce Biosciences (SPRB) CEO Javier Szwarcberg will join an October 22, 2026 fireside chat.
- ➤Tralesinidase alfa remains in late-stage development for MPS IIIB treatment.
- ➤TA-ERT has received four FDA designations, including Breakthrough Therapy Designation.
Spruce Biosciences to Participate in the Craig-Hallum Biotech Catalyst Conference
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will participate in a fireside chat at the Craig-Hallum Biotech Catalyst Conference on October 22, 2026.
Get started
Create a free account to read the full story.